An Interesting Case Report of Myasthenia Gravis Exacerbation Induced by Durvalumab.
adverse effects
cancer immunotherapy
immune check-point inhibitor
myasthenia gravis exacerbation
non-small-cell lung carcinoma
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
accepted:
18
07
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
23
8
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors are novel therapy for a wide range of malignancies. They have been associated with numerous side effects resulting in pulmonary, dermatological, gastrointestinal, and neurological complications. There are few reported cases of myasthenia gravis exacerbation from immune checkpoint inhibitors. We present a case of an 82-year-old woman with a history of myasthenia gravis in remission and non-small cell lung cancer who presented with diplopia, dyspnea, and generalized weakness after three cycles of durvalumab. She was diagnosed with a myasthenic crisis and was treated with high-dose steroids and plasmapheresis.
Identifiants
pubmed: 35989744
doi: 10.7759/cureus.26985
pmc: PMC9381854
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e26985Informations de copyright
Copyright © 2022, Abidoye et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Med Case Rep. 2021 May 31;15(1):278
pubmed: 34053457
Case Rep Oncol Med. 2014;2014:703828
pubmed: 25136468
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
J Immunother Cancer. 2019 Nov 21;7(1):319
pubmed: 31753014
JAMA Netw Open. 2022 Apr 1;5(4):e227722
pubmed: 35438755
Neurology. 2017 Sep 12;89(11):1127-1134
pubmed: 28821685